Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer

Shingo Kanaji, Satoshi Suzuki, Yoshiko Matsuda, Hiroshi Hasegawa, Masashi Yamamoto, Kimihiro Yamashita, Taro Oshikiri, Takeru Matsuda, Tetsu Nakamura, Yasuo Sumi, Yoshihiro Kakeji, Shingo Kanaji, Satoshi Suzuki, Yoshiko Matsuda, Hiroshi Hasegawa, Masashi Yamamoto, Kimihiro Yamashita, Taro Oshikiri, Takeru Matsuda, Tetsu Nakamura, Yasuo Sumi, Yoshihiro Kakeji

Abstract

Gastrectomy with D2 lymph node dissection has become the global standard procedure for locally advanced gastric cancer to maximally reduce locoregional recurrence. In East Asia, based on the evidence of the ACTS-GC and the CLASSIC trials, postadjuvant chemotherapy with S-1 monotherapy or capecitabine and oxaliplatin after curative D2 gastrectomy is the current standard strategy. However, approximately 20% to 30% of patients still develop distant recurrence even after these postadjuvant chemotherapies, especially in those with pathological stage III disease. This review summarizes recent (2008-2018) evidence on the benefits of adjuvant therapy for locally advanced gastric cancer. JACRO GC-07, a Phase III trial, recently showed a superior 3-year recurrence-free survival of the S-1 plus docetaxel regimen in comparison to S-1 monotherapy for patients with pathological stage III gastric cancer after curative D2 gastrectomy. With regard to recent new evidence on neoadjuvant strategy, JCOG0501, a Phase III trial, did not show any superiority in 3-year overall survival (OS) of additional neoadjuvant chemotherapy with S-1/cisplatin over postadjuvant S-1 monotherapy in scirrhous type gastric cancer. Further clinical trials of neoadjuvant chemotherapy are ongoing to improve the poor prognosis for gastric cancer with extensive lymph node metastases. These trials could lead to new evidence for improved treatment of gastric cancer in the near future.

Keywords: D2 lymph node dissection; gastric cancer; neoadjuvant chemotherapy; periadjuvant chemotherapy; postadjuvant chemotherapy; recurrence pattern.

References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
    1. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta‐analysis. JAMA. 2010;303(17):1729–37.
    1. Kanda M, Kodera Y, Sakamoto J. Updated evidence on adjuvant treatments for gastric cancer. Expert Rev Gastroenterol Hepatol. 2015;9(12):1549–60.
    1. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG‐directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.
    1. Sasako M, Sakuramoto S, Katai H, et al. Five‐year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‐1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.
    1. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5‐year follow‐up of an openlabel, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.
    1. Ahn HS, Lee HJ, Hahn S, et al. Evaluation of the Seventh American Joint Committee on Cancer/International Union Against Cancer classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer. 2010;116(24):5592–8.
    1. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15‐year follow‐up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.
    1. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with paraaortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.
    1. Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–23.
    1. Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest. Cancer Res. 2008;2(3):137–44.
    1. Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; The ESMO . Guidelines working group. gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol. 2010;21(Suppl 5):v50–4.
    1. Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11(5):531–46.
    1. Adjuvant Chemotherapy Trial of TS‐1 for Gastric Cancer (ACTS‐GC) 5‐years follow‐up report (in Japanese) Taiho Pharmaceutical Co., Ltd. Study report. No. 717, 2017
    1. Kodera Y, Ishiyama A, Yoshikawa T, et al. A feasibility study of postoperative chemotherapy with S‐1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer. 2010;13(3):197–203.
    1. Takahari D, Hamaguchi T, Yoshimura K, et al. Feasibility study of adjuvant chemotherapy with S‐1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol. 2011;67(6):1423–8.
    1. Kurimoto K, Ishigure K, Mochizuki Y, et al. A feasibility study of postoperative chemotherapy with S‐1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106). Gastric Cancer. 2015;18(2):354–9.
    1. Kodera Y, Yoshida K, Kochi M, et al. A randomized phase III study comparing S‐1 plus docetaxel with S‐1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC‐07 trial). 2018 ASCO Annual Meeting. J Clin Oncol 2018; 36: abstr 4007.
    1. Yoshikawa T, Terashima M, Mizusawa J, et al. A randomized phase III trial comparing 4 courses and 8 courses of S‐1 adjuvant chemotherapy for p‐stage II gastric cancer: JCOG1104 (OPAS‐1). ESMO 2017 Congress. Ann Oncol 2017; 5: v209–68.
    1. Terashima M, Yoshikawa T, Mizusawa J, et al. Updated report of a randomized phase III trial comparing 4 and 8 courses of S‐1 adjuvant chemotherapy for p‐stage II gastric cancer: JCOG1104 (OPAS‐1). 2018 ASCO Annual Meeting. J Clin Oncol 2018; 36: abstr 4024.
    1. Fujitani K, Kurokawa Y, Takeno A, et al. Time to initiation or duration of S‐1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer. 2018;21(3):446–52.
    1. Fujitani K, Tamura S, Kimura Y, et al. Three‐year outcomes of a phase II study of adjuvant chemotherapy with S‐1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer. 2014;17(2):348–53.
    1. Kawabata R, Fujitani K, Tamura S, et al. Three‐year outcomes of a phase II study of adjuvant chemotherapy with S‐1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). ESMO 2017 Congress. Ann Oncol. 2017; 28: (suppl_3, 1), mdx261.086. 10.1093/annonc/mdx261.086
    1. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30(3):268–73.
    1. Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.
    1. Ito S, Sano T, Mizusawa J, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S‐1 followed by gastrectomy with D2 plus para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20(2):322–31.
    1. Association Japanese Gastric Cancer . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
    1. Iwasaki Y, Terashima M, Mizusawa J, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S‐1 plus cisplatin for type 4 or large type 3 gastric cancer: Japan Clinical Oncology Group study (JCOG0501). 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018; abstr 4046.
    1. Fukagawa T, Katai H, Mizusawa J, et al. A prospective multi‐institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21(1):68–73.
    1. Al‐Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro‐oesophageal junction adenocarcinoma (FLOT4‐AIO): results from the phase 2 part of a multicentre, open‐label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708.
    1. Al‐Batran SE, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4‐AIO): a multicenter, randomized phase 3 trial. 2017 ASCO Annual Meeting. 2018. J Clin Oncol. 2017; 35: suppl 15, 4004
    1. Aoyama T, Nishikawa K, Fujitani K, et al. Early results of a randomized two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S‐1 and docetaxel/cisplatin/S‐1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Ann Oncol. 2017;28(8):1876–81.
    1. Bose K, Franck C, Müller MN, Canbay A, Link A, Venerito M. Perioperative Therapy of Oesophagogastric Adenocarcinoma: mainstay and Future Directions. Gastroenterol Res Pract. 2017;2017:5651903.
    1. Yoshikawa T, Morita S, Tanabe K, et al. Survival results of a randomised two‐by‐two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S‐1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 2016;62:103–11.
    1. Kataoka K, Tokunaga M, Mizusawa J, et al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2‐positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Jpn J Clin Oncol. 2015;45(11):1082–6.
    1. Terashima M, Kim Y, Yeh T, et al. ATTRACTION‐05 (ONO‐4538‐38/BMS CA209844): A randomized, multicenter, double‐blind, placebo‐ controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction cancer. Annals of Oncology (2017) 28 (suppl_5): v209‐68. ESMO 2017 Congress. Ann Oncol 2017; 28 (suppl_5): v209‐68. 10.1093/annonc/mdx369
    1. Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE‐585: Phase 3 study of chemotherapy (chemo) plus pembrolizumab (pembro) vs chemo plus placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer. 2018 ASCO Annual Meeting. J Clin Oncol 36, 2018; abstr 4136.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera